Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 583

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

All-trans retinoic acid/As 2 O 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

Open access
Shen, Zhi-Xiang, Shi, Zhan-Zhong, Fang, Jing, Gu, Bai-Wei, Li, Jun-Min, Zhu, Yong-Mei, Shi, Jing-Yi, Zheng, Pei-Zheng, Yan, Hua, Liu, Yuan-Fang, Chen, Yu, Shen, Yang, Wu, Wen, Tang, Wei, Waxman, Samuel, de Thé, Hugues, Wang, Zhen-Yi, Chen, Sai-Juan, Chen, Zhu·2004·Proceedings of the National Academy of Sciences

Abstract

Both all-trans retinoic acid (ATRA) and arsenic trioxide (As 2 O 3 ) have proven to be very effective in obtaining high clinical complete remission (CR) rates in acute promyelocytic leukemia (APL), but they had not been used jointly in an integrated treatment protocol for remission induction or maintenance among newly diagnosed APL patients. In this study, 61 newly diagnosed APL subjects were randomized into three treatment groups, namely by ATRA, As 2 O 3 , and the combination of the two drugs. CR was determined by hematological analysis, tumor burden was examined with real-time quantitative RT-PCR of the PML-RAR α (promyelocytic leukemia - retinoic acid receptor α) fusion transcripts, and side effects were evaluated by means of clinical examinations. Mechanisms possibly involved were also investigated with cellular and molecular biology methods. Although CR rates in three groups were all high (≥90%), the time to achieve CR differed significantly, with that of the combination group being the shortest one. Earlier recovery of platelet count was also found in this group. The disease burden as reflected by fold change of PML-RARα transcripts at CR decreased more significantly in combined therapy as compared with ATRA or As 2 O 3 mono-therapy ( P < 0.01). This difference persisted after consolidation ( P < 0.05). Importantly, all 20 cases in the combination group remained in CR whereas 7 of 37 cases treated with mono-therapy relapsed ( P < 0.05) after a follow-up of 8–30 months (median: 18 months). Synergism of ATRA and As 2 O 3 on apoptosis and degradation of PML-RARα oncoprotein might provide a plausible explanation for superior efficacy of combinative therapy in clinic. In conclusion, the ATRA/As 2 O 3 combination for remission/maintenance therapy of APL brings much better results than either of the two drugs used alone in terms of the quality of CR and the status of the disease-free survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0400053101

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 583

Metadata

Authors
Shen, Z.-X., Shi, Z.-Z., Fang, J., Gu, B.-W., Li, J.-M., Zhu, Y.-M., Shi, J.-Y., Zheng, P.-Z., Yan, H., Liu, Y.-F., Chen, Y., Shen, Y., Wu, W., Tang, W., Waxman, S., de Thé, H., Wang, Z.-Y., Chen, S.-J., & Chen, Z.
Venue
Proceedings of the National Academy of Sciences
Published
2004-03-24
Volume
101
Issue
15
Pages
5328-5335
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2046705094
Cited by
583
References
47
FWCI
11.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: All-trans retinoic acid/As 2 O 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. https://app.cochat.ai/papers/10.1073/pnas.0400053101
The paper
Shen, Z.-X., Shi, Z.-Z., Fang, J., Gu, B.-W., Li, J.-M., Zhu, Y.-M., Shi, J.-Y., Zheng, P.-Z., Yan, H., Liu, Y.-F., Chen, Y., Shen, Y., Wu, W., Tang, W., Waxman, S., de Thé, H., Wang, Z.-Y., Chen, S.-J., & Chen, Z. (2004). All-trans retinoic acid/As 2 O 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0400053101

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.